← All trials
NCT03406715
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2018
- Primary completion
- Apr 30, 2020
- Completion date
- Apr 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 41
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of South FloridaLead sponsor
- University of South FloridaOverall official - principal investigator
- MultiVir, Inc.Collaborator
- Bristol-Myers SquibbCollaborator
- University of South FloridaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.